Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: Current Status and Future Direction

Table 1

REVEAL registry demographic and diagnostic comparison.

	IPAH	CTD	SLE-aPAH	SSc-aPAH
Total # of patients	1251	641	110	399
Patients newly diagnosed at enrollment (%)	14	15	14	16
Age (years)	50.1 ± 17.5	57.1 ± 13.7	45.5 ± 11.9	61.8 ± 11.1
Sex, (#)
Female	987	578	104	353
Male	264	63	6	46
Race (%)
White	74.8	71.8	37.4	83.9
African-American	11.7	16.5	31.8	10.9
Hispanic	8.3	7.5	17.8	3.6
Other	5.2	4.2	13.1	1.6
Raynaud phenomenon (%)	1.4	26.5	13.6	32.6
Renal insufficiency (%)	3.9	6.9	4.6	8.7
Time between diagnostic RHC and enrollment (months)	41.1 ± 44.1	27.2 ± 29.9	34.4 ± 39.1	24.2 ± 24.1
BNP (pg/mL)	245.6 ± 427.2	432.8 ± 789.1	263.8 ± 338.8	552.2 ± 977.8
DLCO (%)	63.6 ± 22.1	44.9 + 18	53.3 ± 19.5	41.2 ± 16.3
Immunosuppressive therapy (%)	1.3	11.9	22	6.8
Alive at 1 year (%)	93	86	94	82